|
|
 |
|
|
 Printer Friendly
|
|
|
|
          |
|
|
|
|
|
| IBCSG 25-02 / BIG 3-02 : TEXT - Tamoxifen and Exemestane Trial |
|
|
|
Trial Status: | Open to patient entry |
|
|
|
|
Treatment type: | Hormone |
|
|
|
|
Stage of Disease: | Early |
|
|
|
|
Intent of Treatment: | Anticancer |
|
|
|
|
|
|
|
Title: |
|
|
| A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer. |
|
|
|
|
|
Summary: |
|
|
| Chemotherapy, hormone tablets, and turning off the ovaries all reduce the risk of breast cancer coming back in young women with early breast cancer with positive hormone receptors. But it is unclear whether all three are necessary and how best to combine them. This international randomised trial will determine if exemestane or tamoxifen is the better hormone tablet for women already having treatment to turn off their ovaries. In this trial the doctor and patient may decide whether or not to include chemotherapy as part of the patient’s treatment. |
|
|
|
|
|
Coordinating Group: |
|
|
Australia and New Zealand:
- ANZ Breast Cancer Trials Group (ANZ BCTG)
International: - International Breast Cancer Study Group (IBCSG)
- Breast International Group (BIG)
|
|
|
For more information:
Women who are interested in taking part in a clinical trial should discuss this with their doctor. In addition, please view links to other websites that provide information about clinical trial participation. |
|
|
|
|